Pregnancy outcomes in patients treated with upadacitinib: Analysis of data from clinical trials and postmarketing reports
Drug Saf 2024 doi: 10.1007/s40264-024-01454-0 Epub ahead of print
This study by Mahadevan, et al. evaluated pregnancy outcomes in patients exposed to upadacitinib during pregnancy. Rates of adverse pregnancy outcomes with upadacitinib exposure were comparable to rates observed in the general population or patients with autoimmune inflammatory diseases not receiving upadacitinib. The data were limited for in utero exposure to upadacitinib, so definitive conclusions cannot be drawn regarding the effect of upadacitinib on pregnancy outcomes.
Clinical trial cases and postmarketing data were analysed separately. Upadacitinib exposure was evaluated in pregnant patients with RA, PsA, axSpA, ulcerative colitis, Crohn’s disease, and atopic dermatitis.
Keywords:
